TRACON(TCON) - 2022 Q4 - Annual Report

Clinical Trials and Efficacy - The ENVASARC Phase 2 pivotal trial is enrolling a total of 160 patients, with the primary objective to exceed the known 4% objective response rate (ORR) of Votrient® (pazopanib) for patients with refractory undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) [17] - The trial aims to demonstrate at least 86% power to show that the lower bound of the 95% confidence interval is greater than 5% in each cohort, which is necessary for potential accelerated approval by the FDA [17] - The ENVASARC trial has shown a double-digit ORR in interim analyses, exceeding the prespecified futility rule, indicating promising efficacy for envafolimab monotherapy and in combination with Yervoy [19] - Envafolimab has been dosed in over 1,000 patients across more than 7 clinical trials, including pivotal trials in MSI-H/dMMR cancer patients [39] - The pivotal Phase 2 trial for Envafolimab in soft tissue sarcoma is expected to provide interim data in Q3 2023 and final data by mid-2024 [30] - Envafolimab demonstrated a 32% confirmed overall response rate (ORR) in 41 patients with MSI-H/dMMR colorectal cancer who failed prior treatments, comparable to 28% for Opdivo and 33% for Keytruda [64] - In the overall population of MSI-H/dMMR cancer patients (n=103), the ORR was 43%, with 92% of patients achieving a duration of response (DOR) of at least 12 months [64] - A Phase 2 trial of TRC102 in lung cancer aims to improve the one-year progression-free survival rate from 56% to 75% [24] - TRC102 has shown good tolerability and promising anti-tumor activity in initial clinical trials with over 100 patients, particularly in combination with Alimta® and Temodar® [24] - A Phase 1 trial of TRC102 in combination with chemoradiation for locally advanced non-squamous non-small cell lung cancer achieved a 100% objective response rate (ORR) among 15 patients, significantly higher than historical data [90] - In a Phase 2 trial for recurrent glioblastoma, 10.5% of patients showed clinical benefit, with two patients achieving PFS beyond 11 months [93] Regulatory and Market Considerations - The FDA granted fast track designation for envafolimab for patients with locally advanced, unresectable or metastatic UPS and MFS, with expectations to submit a biologics license application (BLA) in 2024 if positive data is obtained [20] - The FDA regulates the company's product candidates, requiring compliance with extensive regulations before marketing approval [152] - The FDA's goal is to review 90% of priority marketing applications within six months and 90% of standard applications within ten months [158] - The Orphan Drug Act provides a seven-year exclusive marketing period for drugs approved for rare diseases affecting fewer than 200,000 persons in the U.S. [163] - The U.S. provides a 12-year data exclusivity period for innovator biologic products from the date of first licensure [165] - The EU offers a data exclusivity period of 10 to 11 years for similar biological medicinal products, requiring the reference product to be authorized for at least 8 years [167] - Japan has a market exclusivity period of 8 years for new drug approvals, during which generic applications cannot be submitted [170] - The FDA's Fast Track program facilitates the development and review of drugs for serious conditions, potentially leading to priority review within 6 months [171] - Coverage and reimbursement for approved products depend on third-party payors, who may challenge prices and impose restrictions [175] - Governments are implementing cost-containment measures, including price controls, which could limit net revenue and results for the company [176] Financial and Operational Risks - The company has incurred operating losses since inception and anticipates continued substantial losses, raising concerns about its ability to achieve profitability [15] - The company is heavily dependent on the success of envafolimab and requires substantial additional financing to continue its drug development efforts [15] - The ongoing military conflict between Ukraine and Russia, along with the COVID-19 pandemic, poses potential risks to the company's operations and financial condition [14] - The company faces intense competition and rapid technological change, which may adversely affect its financial condition and ability to commercialize its product candidates [15] Collaborations and Agreements - I-Mab's strategic partnership with Kalbe Genexine Biologics could yield up to $340 million in potential payments for TJ004309 [27] - The Envafolimab Collaboration Agreement allows the company to develop and commercialize envafolimab for sarcoma in North America, with tiered royalties on net sales ranging from the teens to mid-double digits [96][98] - The company has entered into a collaboration agreement with Eucure and Biocytogen for the development of YH001, a CTLA-4 antibody, with exclusive rights for commercialization in North America [102] - The company has collaboration agreements with I-Mab for the development of multiple immuno-oncology programs, including the CD73 antibody TJ004309 [108] - Under the TJ004309 Agreement, the company will bear the costs of filing an IND application and Phase 1 clinical trials, while sharing costs equally for Phase 2 trials [109] Intellectual Property and Patents - The company relies on a patenting strategy focused on protein and small molecule therapeutics, with patents for its candidates expected to expire between 2027 and 2030 [142] - The company holds an exclusive license for envafolimab's intellectual property rights in North America, with a non-exclusive license for clinical trials in the EU [145] - Eucure has an issued patent for YH001 in the U.S., expiring in 2037, allowing for the treatment of multiple human indications [146] - The company holds issued patents for TRC102 in multiple countries, with expiration expected in 2027 and 2031 for different combinations [147][148] - A non-exclusive license for TJ004309 in North America is held from I-Mab, which retains ownership of the related intellectual property rights [149] - The company relies on trade secrets, trademarks, and know-how to maintain its competitive position, protected by confidentiality agreements [151] Manufacturing and Development - Envafolimab is manufactured by AlphaMab in China, with fill finish performed by a U.S. contract manufacturer, at pre-negotiated prices [131] - The company utilizes a CRO-independent product development platform to enhance capital efficiency and expedite clinical trial processes [30] Employee and Corporate Information - As of December 31, 2022, the company had 18 full-time employees, with 12 involved in research, development, or manufacturing [184] - Access to the Annual Report on Form 10-K and quarterly reports on Form 10-Q is available through the investor section of the company's website without any charge [186] - The company does not assume any obligation to update forward-looking statements unless required by law [186] - The Annual Report contains references to trademarks, but does not imply endorsement or sponsorship by other companies [187] - There are no applicable quantitative and qualitative disclosures about market risk in the current report [475]